A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and ...
An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like ...
Supported by a grant (1R01HL166246, to Dr. Bendapudi) from the National Institutes of Health and by the Luick Family Fund of the Department of Pathology at Massachusetts General Hospital. Disclosure ...
SAN DIEGO — Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated immune thrombocytopenia (ITP). In the LUNA ...
Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. The drug, which the French pharma giant acquired through a $3.7 billion buyout of ...
While Sanofi originally had its eye on tolebrutinib when it purchased its partner Principia Biopharma for $3.7 billion five years ago, another one of the Bruton tyrosine kinase (BTK) inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results